# Pembrolizumab Alone and In Combination With Acalabrutinib (ACP-196) in Subjects With Advanced Non-small Cell Lung Cancer

> **NCT02448303** · PHASE2 · COMPLETED · sponsor: **Acerta Pharma BV** · enrollment: 74 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Acalabrutinib

## Key facts

- **NCT ID:** NCT02448303
- **Lead sponsor:** Acerta Pharma BV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2018-03
- **Final completion:** 2018-06
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2019-09-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02448303

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02448303, "Pembrolizumab Alone and In Combination With Acalabrutinib (ACP-196) in Subjects With Advanced Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02448303. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*